Welcome
@mrdingo, sorry to butt in.. but the trial dosed its first patient in September 2020 (before it listed on the ASX). Phase 1 trial is expected to take 18-24 months, so 18 months would be March 2022 and 24 months would be September 2022.
Once they complete the phase 1 study, they will pivot very quickly into a phase 2 trial which is expected to be a registrational study. This is based on the 5 other FDA approved CAR-T's, 4 were approved after a phase 2 trial and 1 was approved after a phase 1 trial.
They just announced the CRO who will conduct the clinical trials for CHM, starting with opening up new trial sites for the phase 1 study to speed it up. So far they've only recruited from one clinical site at the City of Hope in California. So with more sites, I think they'll comfortably meet the September 2022 completion as that was largely contingent on how many clinical sites would be opened.
First read out of the phase 1 study is expected in Q4, so Oct-Dec. Should include data from the first cohort (lowest dose) and second cohort (double the lowest dose) with the key focus safety, but any tumor shrinkage or progression free survival will be very interesting at such low doses.
(20min delay)